A Randomized, Double-Blind, Single Dose, Four-Period, Four-Treatment, Cross-Over Study Evaluating the Safety of PT001, PT003, PT005 Administered Individually and PT001 + PT005 Delivered Together in Separate Inhalers in Healthy Subjects.

Trial Profile

A Randomized, Double-Blind, Single Dose, Four-Period, Four-Treatment, Cross-Over Study Evaluating the Safety of PT001, PT003, PT005 Administered Individually and PT001 + PT005 Delivered Together in Separate Inhalers in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Formoterol/glycopyrrolate (Primary) ; Formoterol; Glycopyrrolate
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors Pearl Therapeutics
  • Most Recent Events

    • 19 May 2010 Results were presented at the 106th International Conference of the American Thoracic Society.
    • 19 May 2010 Results presented at the annual meeting of the American Thoracic Society.
    • 18 May 2010 Safety and pharmacokinetic data reported at ATS, according to a Pearl Therapetuics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top